Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone

A. Kapitány, L. Tóth, J. Tumpek, I. Csópo, E. Sipos, N. Woolley, J. Partanen, G. Szegedi, E. Oláh, S. Sipka, I. R. Korponay-Szabó

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Coeliac disease is strongly associated with human leukocyte antigen (HLA)-DQ2 or DQ8 genotypes. The diagnosis is based on demonstrating crypt-hyperplastic villous atrophy, endomysial or transglutaminase antibodies and correlation of disease activity with gluten intake. Aim: To evaluate the clinical utility of HLA-DQ typing, when coeliac disease diagnosis had previously been established solely by histology. Methods: HLA-DQ alleles, endomysial and transglutaminase antibodies were investigated and histology slides reviewed in 70 patients diagnosed 2-25 years earlier by small-intestinal biopsy but without measuring endomysial or transglutaminase antibodies. Patients without DQ2 or DQ8 or without unequivocal villous atrophy were followed-up on free diet by using serology and biopsies. Results: All 40 endomysial/transglutaminase antibodies positive patients carried DQ2 or DQ8, and 39 of them had severe villous atrophy. Only 56% of patients without endomysial or transglutaminase antibodies positivity had DQ2 or DQ8 (P <0.001). Seropositivity and relapse developed in 4 of 11 DQ2 positive but in none of 15 DQ2 and DQ8 negative patients on long-term gluten exposure. Conclusions: Coeliac disease diagnosis based solely on histology is not always reliable. HLA-DQ typing is important in identifying DQ2 and DQ8 negative subjects who need revision of their diagnosis, but it does not have additive diagnostic value if endomysial positivity is already known.

Original languageEnglish
Pages (from-to)1395-1402
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume24
Issue number9
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Transglutaminases
Celiac Disease
HLA Antigens
Histology
Antibodies
Atrophy
Glutens
Biopsy
Serology
Alleles
Genotype
Diet
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone. / Kapitány, A.; Tóth, L.; Tumpek, J.; Csópo, I.; Sipos, E.; Woolley, N.; Partanen, J.; Szegedi, G.; Oláh, E.; Sipka, S.; Korponay-Szabó, I. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 24, No. 9, 11.2006, p. 1395-1402.

Research output: Contribution to journalArticle

@article{b197692fc1f44a2882e7a2aa908592bc,
title = "Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone",
abstract = "Background: Coeliac disease is strongly associated with human leukocyte antigen (HLA)-DQ2 or DQ8 genotypes. The diagnosis is based on demonstrating crypt-hyperplastic villous atrophy, endomysial or transglutaminase antibodies and correlation of disease activity with gluten intake. Aim: To evaluate the clinical utility of HLA-DQ typing, when coeliac disease diagnosis had previously been established solely by histology. Methods: HLA-DQ alleles, endomysial and transglutaminase antibodies were investigated and histology slides reviewed in 70 patients diagnosed 2-25 years earlier by small-intestinal biopsy but without measuring endomysial or transglutaminase antibodies. Patients without DQ2 or DQ8 or without unequivocal villous atrophy were followed-up on free diet by using serology and biopsies. Results: All 40 endomysial/transglutaminase antibodies positive patients carried DQ2 or DQ8, and 39 of them had severe villous atrophy. Only 56{\%} of patients without endomysial or transglutaminase antibodies positivity had DQ2 or DQ8 (P <0.001). Seropositivity and relapse developed in 4 of 11 DQ2 positive but in none of 15 DQ2 and DQ8 negative patients on long-term gluten exposure. Conclusions: Coeliac disease diagnosis based solely on histology is not always reliable. HLA-DQ typing is important in identifying DQ2 and DQ8 negative subjects who need revision of their diagnosis, but it does not have additive diagnostic value if endomysial positivity is already known.",
author = "A. Kapit{\'a}ny and L. T{\'o}th and J. Tumpek and I. Cs{\'o}po and E. Sipos and N. Woolley and J. Partanen and G. Szegedi and E. Ol{\'a}h and S. Sipka and Korponay-Szab{\'o}, {I. R.}",
year = "2006",
month = "11",
doi = "10.1111/j.1365-2036.2006.03133.x",
language = "English",
volume = "24",
pages = "1395--1402",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Diagnostic significance of HLA-DQ typing in patients with previous coeliac disease diagnosis based on histology alone

AU - Kapitány, A.

AU - Tóth, L.

AU - Tumpek, J.

AU - Csópo, I.

AU - Sipos, E.

AU - Woolley, N.

AU - Partanen, J.

AU - Szegedi, G.

AU - Oláh, E.

AU - Sipka, S.

AU - Korponay-Szabó, I. R.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Coeliac disease is strongly associated with human leukocyte antigen (HLA)-DQ2 or DQ8 genotypes. The diagnosis is based on demonstrating crypt-hyperplastic villous atrophy, endomysial or transglutaminase antibodies and correlation of disease activity with gluten intake. Aim: To evaluate the clinical utility of HLA-DQ typing, when coeliac disease diagnosis had previously been established solely by histology. Methods: HLA-DQ alleles, endomysial and transglutaminase antibodies were investigated and histology slides reviewed in 70 patients diagnosed 2-25 years earlier by small-intestinal biopsy but without measuring endomysial or transglutaminase antibodies. Patients without DQ2 or DQ8 or without unequivocal villous atrophy were followed-up on free diet by using serology and biopsies. Results: All 40 endomysial/transglutaminase antibodies positive patients carried DQ2 or DQ8, and 39 of them had severe villous atrophy. Only 56% of patients without endomysial or transglutaminase antibodies positivity had DQ2 or DQ8 (P <0.001). Seropositivity and relapse developed in 4 of 11 DQ2 positive but in none of 15 DQ2 and DQ8 negative patients on long-term gluten exposure. Conclusions: Coeliac disease diagnosis based solely on histology is not always reliable. HLA-DQ typing is important in identifying DQ2 and DQ8 negative subjects who need revision of their diagnosis, but it does not have additive diagnostic value if endomysial positivity is already known.

AB - Background: Coeliac disease is strongly associated with human leukocyte antigen (HLA)-DQ2 or DQ8 genotypes. The diagnosis is based on demonstrating crypt-hyperplastic villous atrophy, endomysial or transglutaminase antibodies and correlation of disease activity with gluten intake. Aim: To evaluate the clinical utility of HLA-DQ typing, when coeliac disease diagnosis had previously been established solely by histology. Methods: HLA-DQ alleles, endomysial and transglutaminase antibodies were investigated and histology slides reviewed in 70 patients diagnosed 2-25 years earlier by small-intestinal biopsy but without measuring endomysial or transglutaminase antibodies. Patients without DQ2 or DQ8 or without unequivocal villous atrophy were followed-up on free diet by using serology and biopsies. Results: All 40 endomysial/transglutaminase antibodies positive patients carried DQ2 or DQ8, and 39 of them had severe villous atrophy. Only 56% of patients without endomysial or transglutaminase antibodies positivity had DQ2 or DQ8 (P <0.001). Seropositivity and relapse developed in 4 of 11 DQ2 positive but in none of 15 DQ2 and DQ8 negative patients on long-term gluten exposure. Conclusions: Coeliac disease diagnosis based solely on histology is not always reliable. HLA-DQ typing is important in identifying DQ2 and DQ8 negative subjects who need revision of their diagnosis, but it does not have additive diagnostic value if endomysial positivity is already known.

UR - http://www.scopus.com/inward/record.url?scp=33750020559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750020559&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.03133.x

DO - 10.1111/j.1365-2036.2006.03133.x

M3 - Article

C2 - 17059521

AN - SCOPUS:33750020559

VL - 24

SP - 1395

EP - 1402

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -